Digestive Diseases and Sciences

, Volume 47, Issue 3, pp 573–578

Identification of Spasmolytic Polypeptide Expressing Metaplasia (SPEM) in Remnant Gastric Cancer and Surveillance Postgastrectomy Biopsies


  • Hirokazu Yamaguchi
    • Department of Gastrointestinal Surgery, Graduate School of MedicineUniversity of Tokyo
    • Institute of Molecular Medicine and GeneticsMedical College of Georgia
  • James R. Goldenring
  • Michio Kaminishi
    • Department of Gastrointestinal Surgery, Graduate School of MedicineUniversity of Tokyo
  • Jeffrey R. Lee

DOI: 10.1023/A:1017920220149

Cite this article as:
Yamaguchi, H., Goldenring, J.R., Kaminishi, M. et al. Dig Dis Sci (2002) 47: 573. doi:10.1023/A:1017920220149


Following gastrectomy, the remnant oxyntic mucosa is at increased risk of developing adenocarcinoma. Alkaline pancreaticoduodenal reflux, carcinogen production from intragastric bacterial overgrowth, denervation, and devascularization have been implicated in this malignant transformation. Recent reports have described a novel spasmolytic polypeptide (SP) expressing metaplastic lineage designated as SPEM. This lineage has been identified in the mucosa surrounding gastric adenocarcinomas, and SP staining has been observed in the cells of surface dysplasia and invasive malignancy. In this study we describe 19 cases of remnant gastric adenocarcinoma from Japan. In addition, we studied surveillance biopsies in 90 patients who underwent antrectomy for carcinoma. SPEM was identified in the mucosa surrounding 88% of the remnant cancers, as well as in 61% of the surveillance biopsies. In the malignant resections, 67% of the surface dysplasia displayed SP positive cells, and 25% revealed SP immunostaining within invasive malignant cells. These findings implicate SPEM as a potential precursor lesion of gastric adenocarcinoma.

remnant adenocarcinomaspasmolytic polypeptideSPEMintestinal metaplasia

Copyright information

© Plenum Publishing Corporation 2002